Lepu Bio-B (02157) announced that on November 13, 2023, the company entered into a CDMO service framework agreement with Lepu Healthcare. The company and/or its subsidiaries agreed to provide CDMO technical services to Lepu Medical and/or its subsidiaries.
The Group is mainly engaged in the research and development of its drug candidates and operates a bioreactor production line that complies with GMP standards. The production line has been in operation since the end of 2019.